19:17 , Jul 17, 2019 |  BC Extra  |  Company News

Gilead CSO McHutchison, two others, out as O’Day reshapes his team

With the departures of CSO John McHutchison, Chief Patient Officer Gregg Alton and EVP of Human Resources Katie Watson announced Wednesday, Daniel O'Day will be left with less than half of the 10-person senior management...
00:51 , May 31, 2019 |  BC Innovations  |  Targets & Mechanisms

Targeting cancer evolution offers a way to foil drug resistance

A growing crop of researchers and companies are tackling cancer drug resistance by preempting tumors’ tendencies to adapt, rather than responding to resistance after it develops. Though still in their infancy, these therapies could get...
10:32 , Apr 22, 2019 |  BC Extra  |  Company News

Lilly pays $35M up front to partner with Avidity on oligo conjugates

Lilly partnered with Avidity to develop antibody-oligonucleotide conjugates to treat immune diseases, with the biotech receiving $20 million up front and a $15 million investment. Avidity Biosciences LLC (La Jolla, Calif.) is eligible to receive...
23:44 , Apr 18, 2019 |  BC Extra  |  Company News

Three steps forward, one step back for AI drug discovery

Two AI drug discovery and development deals this week, and new hits announced from an existing collaboration, show sustained momentum in the space despite news that IBM will stop seeking partnerships for its Watson for...
22:41 , Apr 11, 2019 |  BC Extra  |  Company News

Medidata launches AI venture

Medidata launched Acorn AI to develop products that integrate clinical trial data with translational and real world information that could help life science companies and academic institutions identify responders in patient populations and improve trial...
22:33 , Mar 27, 2019 |  BC Innovations  |  Translation in Brief

A mitochondrial shield from cell death

An IBM-Mount Sinai team has challenged the prevailing idea that high mitochondrial counts in tumor cells enhance cancer’s sensitivity to apoptosis-inducing therapies by showing that low numbers of the organelle actually do the trick. The...
01:47 , Feb 15, 2019 |  BC Week In Review  |  Company News

IBM, Broad to use AI to improve CV genetic risk prediction

The Broad Institute of MIT and Harvard and the IBM Watson Health business of IBM Corp. (NYSE:IBM) have teamed up to develop artificial intelligence algorithms to improve the predictive power of polygenic scoring of cardiovascular...
21:15 , Feb 13, 2019 |  BC Extra  |  Company News

IBM, Broad to use AI to improve CV genetic risk prediction

The Broad Institute of MIT and Harvard and the IBM Watson Health business of IBM Corp. (NYSE:IBM) have teamed up to develop artificial intelligence algorithms to improve the predictive power of polygenic scoring of cardiovascular...
05:09 , Jan 5, 2019 |  BioCentury  |  Product Development

Bristol-Myers’ next phoenix act?

Bristol-Myers Squibb Co. will now be in the driver’s seat to monetize the assets gained from the myriad deals Celgene Corp. has forged. The pharma will need to mimic its history of using well-timed acquisitions...
00:50 , Jan 5, 2019 |  BC Extra  |  Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...